Pneumococcal conjugate vaccine

Where the papers sit

11 papers from the last 6 months study pneumococcal conjugate vaccine directly · updated from PubMed 1 Nov 2026

• Higher-Valency Pneumococcal Vaccines

  Broader-valency conjugate vaccines are being developed to cover changing serotype distributions and invasive pneumococcal disease. V116 and 24-valent candidates are assessed alongside PCV13 and polysaccharide vaccine for safety and immunogenicity in adults and higher-risk children. Revaccination studies show that the initial platform shapes later antibody profiles, making sequence choice clinically relevant. Disease burden, resistance, and immunization data are being used to estimate the value of 20- and 21-valent programs.

  5 papers · 45.5%

• Pneumococcal Vaccination Economics

  PCV20 and PCV21 are being judged not only by disease prevention but also by population health and economic value. Models use QALYs, deaths, pneumonia outcomes, and incremental cost-effectiveness ratios to compare adult and pediatric vaccination strategies. Real-world pediatric data examine effectiveness against hypoxemia in suspected pneumonia. Priority-setting analyses increasingly combine economic results with broader criteria for vaccine allocation.

  4 papers · 36.4%

• Infant Pneumococcal Immunization

  Infant schedules are being compared by the breadth and durability of IgG responses through age five. Randomized evidence contrasts PCV15 and PCV20 with PCV13, while follow-up compares one- versus two-dose primary series of PCV10 and PCV13. Core endpoints are serotype-specific immunogenicity and protection relevant to invasive pneumococcal disease. The open question is whether higher valency or fewer infant doses can preserve protection without weakening antibody responses.

  2 papers · 18.2%